Innate Pharma SA

F:IDDA

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

France FR

Employees

163

IPO date

Oct 31, 2006

Innate Pharma is a French biotechnology company that develops cancer treatments based on the immune system, especially therapies that use natural killer, or NK, cells and antibodies. It does not make broad consumer products; it builds drug candidates and advances them through research, clinical testing, and partnerships with larger drugmakers.

The company’s main customers are not patients directly, but pharmaceutical partners, hospitals, and the healthcare system through future drug sales if its programs win approval. It earns money through collaboration agreements, research funding, licensing deals, and potential milestone and royalty payments tied to its drug pipeline. Like many biotech companies, much of its value comes from turning lab science into medicines that other companies can help develop and commercialize.

What makes Innate Pharma different is its focus on the biology of innate immunity, a branch of the immune system that can attack cancer cells in a different way from standard antibody or chemotherapy approaches. That specialization gives it a clear role as a research-driven drug developer and as a partner for larger companies looking for new cancer therapies.